In the second stage, 60 healthy subjects and TB subjects aged 3-17 years and 66-75 years old are divided into different groups through a randomized, open, single-arm method with the target dose. Evaluate the safety, tolerance and preliminary efficacy of target dose of EEC in healthy people and TB patients aged 3 to 17 years old and 66 to 75 years old. conditions: Tuberculosis studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: DIAGNOSTIC masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 420 type: ESTIMATED name: 2.5μg/ml EEC name: 5μg/ml EEC name: 5 unit（U） EC measure: Sensitivity of different doses of EEC and control EC in pulmonary tuberculosis patients aged 18 to 65 years ; measure: specificity of different doses of EEC and control EC in healthy subjects aged 18 to 65 years and patients with non-tuberculous lung disease ; measure: The skin test site specific reaction at 4h,8h (only for stage 2);24h, 48h, 72h, 96h, and 7 days after skin test. Those with average diameter of induration/redness is ≥5 mm will be considered to positive. measure: Receiver operator characteristic curve(ROC) of different doses of EEC to evaluate the optimal diagnostic test cut-off value of the test drug. measure: Area under the curve(AUC) of different doses of EEC to evaluate the optimal diagnostic test cut-off value of the test drug. measure: In healthy people, patients with tuberculosis and patients with non-tuberculous lung diseases, the consistency rates of the three detection reagents EEC , EC and IGRA were evaluated respectively. measure: Incidence of adverse events and serious adverse events at injection and non-injection sites，abnormal incidence of laboratory indicators and vital signs during the study period. sex: ALL minimumAge: 3 Years maximumAge: 75 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Beijing Chest Hospital status: RECRUITING city: Beijing state: Beijing zip: 101149 country: China name: Tongqun Zhang role: CONTACT phone: 010-89509134 email: Zhangtongqun@sina.com name: Naihui Chu, PhD role: PRINCIPAL_INVESTIGATOR lat: 39.9075 lon: 116.39723 facility: Wuhan Institute for Tuberculosis Control status: RECRUITING city: Wuhan state: Hubei zip: 430000 country: China name: Min Wang role: CONTACT phone: 13871221841 email: whsfkyyllsc@163.com name: Juan Du, Bachelor role: PRINCIPAL_INVESTIGATOR name: Ronghui Du, Bachelor role: PRINCIPAL_INVESTIGATOR lat: 30.58333 lon: 114.26667 facility: Changde First People's Hospital status: RECRUITING city: Changde state: Hunan zip: 415000 country: China name: Shuxiang Zhou role: CONTACT phone: 0736-7788890 email: 450717196@qq.com name: Tianli Wang, master role: PRINCIPAL_INVESTIGATOR lat: 29.04638 lon: 111.6783 facility: Jiangsu Province Centers for Disease Control and Prevention status: RECRUITING city: Nanjing state: Jiangsu zip: 212400 country: China name: Xiaoyan Ding role: CONTACT phone: 025-83759406 email: ec@jscdc.cn name: Limei Zhu, master role: PRINCIPAL_INVESTIGATOR lat: 32.06167 lon: 118.77778 facility: Xuzhou Infectious Disease Hospital status: RECRUITING city: Xuzhou state: Jiangsu country: China name: Tingting Liu role: CONTACT phone: 0516-68900929 email: xcyllb123@163.com name: Ruimei Zhang, Bachelor role: PRINCIPAL_INVESTIGATOR lat: 34.18045 lon: 117.15707 facility: Public health clinical center of chengdu status: RECRUITING city: Chengdu state: Sichuan zip: 610066 country: China name: Qing Yang role: CONTACT phone: 028-64369118 email: crbykjk@126.com name: Guihui Wu, master role: PRINCIPAL_INVESTIGATOR lat: 30.66667 lon: 104.06667 hasResults: False